Cystic acne usually needs treatment aimed at severe acne, not a stronger version of a basic spot routine. The best-supported option is oral isotretinoin, especially when deep, painful lesions are severe or standard treatments have failed. "Cystic acne" commonly describes deep cysts or nodules on the face, chest, or back. These lesions can scar, so treatment decisions should weigh effectiveness, prior treatment failures, and safety requirements.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What makes cystic acne different?
- How strong is the evidence for isotretinoin?
- What are the main alternatives?
- How should you choose the next step?
What makes cystic acne different?
The American Academy of Dermatology describes severe acne as involving deep, painful cysts or nodules that can leave scars. "Cystic acne" is therefore a useful everyday label, but treatment guidance generally uses terms such as severe or nodular acne. Depth and scarring risk matter more than the number of visible spots.
A few persistent nodules may warrant more attention than many shallow blemishes, particularly when standard topical or oral treatment has already failed. This distinction also explains why procedures and supplements should not replace established treatment. The AAD found insufficient evidence to recommend chemical peels, laser or light devices, microneedling, dietary changes, vitamins, or plant-based alternatives for acne.
How strong is the evidence for isotretinoin?
The 2024 AAD acne guideline recommends oral isotretinoin for severe acne or acne that has not responded to standard topical or oral therapy. It has the clearest clinical role when deep lesions persist and scarring is a concern. A pivotal 33-person randomized trial studied treatment-resistant cystic or conglobate acne. Initially treated participants improved by 95%, while the placebo group experienced a 57% increase in cystic lesions before switching treatment, according to the Journal of the American Academy of Dermatology trial.
That result was dramatic, but the trial was small and published in 1982. It cannot, by itself, show how every patient described today as having "cystic acne" will respond. A later trial offers a more useful comparison. Among 266 people with severe nodular acne, isotretinoin reduced nodules by 95.6% at week 20, compared with 88.7% for doxycycline plus adapalene and benzoyl peroxide. Medically relevant treatment-related adverse events were also more frequent with isotretinoin: 33.8% versus 18.0%, according to the British Journal of Dermatology study.
What are the main alternatives?
A combined regimen can be reasonable when isotretinoin is not yet indicated or its risks outweigh its additional benefit. The comparative trial's doxycycline, adapalene, and benzoyl peroxide regimen produced substantial improvement, although isotretinoin reduced nodules more. Antibiotics should not become an indefinite stand-alone strategy. The AAD recommends limiting oral-antibiotic use and pairing topical or oral antibiotics with benzoyl peroxide to reduce antibiotic resistance.
It also recommends combining topical treatments rather than relying on one product alone. Spironolactone is another evidence-supported option for some adult women with persistent facial acne. In a 410-participant randomized trial, it improved patient-reported outcomes by 24 weeks, with a number needed to treat of five. However, that trial did not specifically study cystic acne, so it does not establish equal effectiveness for severe nodules or cysts.
How should you choose the next step?
Start by identifying the decision you actually face: The U.S. Food and Drug Administration approves isotretinoin for severe recalcitrant nodular acne and warns that it is highly teratogenic.
In the United States, it is dispensed through the restricted iPLEDGE program to reduce embryo-fetal exposure. Bring a clear account of which topical and oral treatments you have used and whether deep lesions are persisting. That information helps frame the central choice: continue combination therapy, consider a different option, or discuss isotretinoin under its required safety controls.
- Deep, painful lesions or possible scarring: seek a dermatology assessment rather than relying on cosmetic procedures or supplements.
- Failure of standard topical or oral treatment: ask whether the AAD criteria for considering isotretinoin fit your case.
- An antibiotic plan: confirm that it includes benzoyl peroxide and a strategy to limit antibiotic use.
- Persistent facial acne in an adult woman: ask whether spironolactone is relevant, while recognizing that its key trial was not cystic-acne-specific.
- Pregnancy potential: discuss isotretinoin's restrictions before treatment decisions are made.
